GlassScriptPhysician profile
Susan J Beil
NPI 1548256407
$471.30
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $94.62 · 2021: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $164.99 | 2019-2021 | |
| Abbvie INC. | $70.36 | 2020-2021 | |
| Avion Pharmaceuticals | $52.32 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $36.25 | 2019 | |
| Agile Therapeutics, INC. | $30.64 | 2021 | |
| Roche Diagnostics Corporation | $26.48 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.74 | 2019 | |
| Duchesnay USA Incorporated | $17.07 | 2019 | |
| Pfizer INC. | $15.33 | 2021 | |
| Coopersurgical, INC. | $15.12 | 2021 | |
| Novo Nordisk INC | $12.05 | 2021 | |
| Lupin INC. | $11.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Beil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.